BioCorRx, Inc
BioCorRx® is a leading-edge healthcare solutions company focused on improving the lives of those struggling with excessive consumption.
The company's business lines include two operational programs in addition to an R&D subsidiary.
OTCQB: BICX
IR Website: https://ir.biocorrx.com/
Headquarters: Anaheim, California
Learn More about BioCorRx at b2idigital.com/biocorrx
TALK TO MANAGEMENT
The BioCorRx management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
BioCorRx® was founded to help people rebuild their lives by overcoming excesses. We believe that with the right support, people can live productive, fulfilling lives. Our leadership is comprised of doctors, forward-thinking experts, as well as some who have experienced the vicious cycle of overconsumption firsthand. We are committed to transforming lives and making the world a better place for us all.
What Makes the BioCorRx® Program Different?
Learn More About BioCorRx at b2idigital.com/biocorrx
CEO Interview: Lourdes Felix Provides Update
Investor Presentation
For a personalized walk-through of the investor presentation, please fill out the form using the link below and the management team of BioCorRx Inc. will be in touch to schedule a meeting.
Stock Chart
Stock Detail
SEC Filings
Financials
Recent Interviews/Media
BioCorRx® Mobile Application
The BioCorRx® Program has is a multi-pronged approach including a peer recovery support mobile application
The program can be done very discreetly with virtually no major disruptions from daily life, with mobile support designed to fit into the patient's everyday life.
Mobile App
|
 |
 |
Objectives and Milestones
-
Seeking FDA approval of implantable pellet
-
Formed a Scientific Advisory board, includes Dr. David Gastfriend, Dr George Woody, and Dr. Evgeny Krupitsky
-
Designed study with the help of the late Dr. Bal S. Brar over 25 years of industry experience as well as worldwide regulatory submission of 50 INDs/510K’s and 505(b)(2)’s; and approval of 8 NDA’s
-
Partnered with Innovative Science Solutions, LLC, a leading scientific consulting firm, to help guide the Company’s regulatory strategy for FDA submission
-
Expanded development and manufacturing relationship with Recro (formerly IriSys) to support BICX104
-
505(B)(2) pathway deemed acceptable by FDA
-
Received NIDA grant of approximately $5.7 million
-
Received FDA Clearance of IND application for BICX104
-
Awarded approx. $3.5 million second phase of NIDA Grant for total of nearly $9.2 million in grant funding to date
Management Overview
Lourdes Felix
CEO, CFO and Director
Lourdes Felix is a female Hispanic entrepreneur and corporate finance executive with 30 years of combined experience in capital markets, public accounting and in the private sector. She presently serves as Chief Executive Officer, Chief Financial Officer and Director of BioCorRx Inc. (OTCQB: BICX). She has been with BioCorRx since October 2012. She has been instrumental in capital procurement, completing multi-million dollar equity financing and accomplished in structuring and negotiating transactions and favorable terms with investment banks. Along with other executives of the company, rebranded the Company and restructured and expanded the business model to position it for long term growth.
Prior to joining BioCorRx her experience was in the private sector, public accounting including audit and public company experience. She has expertise in finance, accounting, budgeting and internal control principals including GAAP, SEC, and SOX Compliance. Thorough knowledge of federal and state regulations. Successfully managed and produced SEC regulatory filings. She has extensive experience in developing and managing financial operations. Lourdes has provided treasury and cash management functions. Excellent leader with a track record of documented contributions leading to improved financial performance, heightened productivity, and enhanced internal controls. Led corporate relationships with various major accounting firms and attorneys in preparing SEC filings and audited financial statements. Lourdes is very active in the Hispanic community and speaks fluent Spanish. Lourdes holds a Bachelor of Science degree in Accounting from University of Phoenix. She is an MBA candidate at D’Amore-McKim School of Business, Northeastern University.
Brady Granier
President and Director
During the 12 years prior to joining BioCorRx® in June of 2013, Brady Granier had been involved in sales management, media sales and business development. Mr. Granier was employed at Clear Channel Media & Entertainment ("CCME"), where he had served in several positions from Account Executive to Director of Business Development and Local Sales Manager. He has also served as the Healthcare Category Manager for the Los Angeles division of CCME, the largest media company in the United States. During his tenure at CCME and other media companies, he worked on marketing campaigns for local businesses and physicians, as well as for national brands such as Neutrogena, New Line Cinema, Paramount Pictures, Samsung, AT&T, Coke, Dr. Pepper, Hansen's, Honda, MGM, Universal Studios and more. He also managed endorsements on the radio for Ryan Seacrest. In 2006, He received the coveted Pinnacle Award from CCME for being the top sales executive in the Western region. While serving as Director of Business Development, Mr. Granier grew new business by 49% in his first year in that role.
Granier was born and raised in the heart of Cajun Country in Southeast Louisiana where he started working at the age of 11 to help support his single mother and younger brother. After graduating with honors from high school, he attended college at Nicholls State University in Thibodaux, LA. He earned his Bachelor of Science degree in Nursing in 1995 and was a member of Sigma Theta Tau Honor Society and Phi Kappa Theta. During his nursing career, he specialized in the critical care areas of ER/ICU/CCU and CICU. He also moonlighted as a home health nurse, critical care air transport nurse and TV studio set medic. In 1996, he moved to California as a travel nurse and spent most of his remaining years in healthcare as the charge nurse in the emergency room at White Memorial Hospital in downtown Los Angeles. Mr. Granier continues to reside in the Los Angeles area with his family. He has also been a volunteer with Big Brothers of America.
Tom Welch
VP of Operations
Welch was a founder and Director of Operations at TAK Management from 2012 until 2015. His responsibilities included placement and training of key personnel, billing, coding, and collections and establishing and maintaining relationships with outside vendors and physicians. Mr. Welch led a team that completely reorganized clinic operations. Tom’s responsibilities included Implementation of policies and procedures as well as creation of standard practice protocols integrated in to multiple locations. Additionally, Tom Implemented traditional media and Social Marketing strategies. Tom was also successful in negotiating reimbursement with major private insurance corporations across the U.S.
Prior to his tenure with TAK Management, Mr. Welch had been involved in the identifying and placement of talented executive level candidates nationwide in healthcare since 1999. Mr. Welch created Benchmark Consulting Group LLC in 2001 in Los Angles California and expanded into Dallas Texas in 2005. He has been actively involved in assisting in infrastructure creation including, front and back office management, billing and coding personnel, clinical management and executive teams. Tom was responsible for negotiating multiple partnership agreements and contracts with major corporations and both the Military and Veterans Administration.
Welch started his career in Healthcare in Omaha Nebraska where he supervised the medivan program while training for his emergency medical technician license with Eastern Ambulance.
Dr. George Fallieras
Medical Consultant
Dr. George N. Fallieras comes from a family of physicians. Dr. Fallieras grew up in Tampa, Florida, and graduated Phi Beta Kappa from the University of Florida. He obtained his M.D. from the University of Tennessee, and did his residency training in New Orleans at the Tulane Health Science Center/Charity Hospital. Dr. Fallieras is double board certified in both Internal Medicine and Pediatrics. He has served as the Medical Director for multiple large Inpatient Hospitalist programs. He is passionate about international medicine and serves on twice yearly missions trips to rural Dominican Republic and Port-au-Prince, Haiti. Dr. Fallieras has served as expert commentary on multiple news, television, and radio outlets.
As a medical director for BioCorRx, he has established ethical and effective protocols.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
BioCorRx Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
b2i digital or its related entities may own securities of the Company.
To comply with Rule 17(b) of the Securities Act of 1933, as amended, b2i Digital must provide full disclosure of all compensation received for investor awareness services provided by the Company. The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.
The BioCorRx management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
• Directly hear the BioCorRx story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible
Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.
